Clinical Trials Industry News More
-
Molecular Insight Pharmaceuticals Advances Solazed™ For Malignant Melanoma Into Phase 1 Clinical Trial
3/23/2010
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced the initiation of a Phase 1 clinical trial of Solazed™ (Ioflubenzamide I-131), the Company's targeted radiotherapeutic drug candidate for treatment of malignant metastatic melanoma.
-
Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5-17 With Grass Pollen Allergy
3/3/2010
In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo (p=0.001).
-
MCG To Conduct First FDA-Approved Stem Cell Trial In Pediatric Cerebral Palsy
2/12/2010
Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.
-
AspenBio Pharma Reports On AppyScore™ Supplemental Clinical Trial Interim Analysis And Provides Guidance On FDA 510(k) Filing
2/11/2010
AspenBio Pharma, Inc. (NASDAQ: APPY) today reported conclusions from its pre-planned, independent, interim analysis of the Company's ongoing supplemental clinical trial of AppyScore™, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outlined next steps for its AppyScore 510(k) filing with the U.S. Food and Drug Administration (FDA).
-
Akebia Announces Positive Results For AKB-6548 Phase 1 Clinical Study
1/7/2010
Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed the first-in-man phase 1a study for AKB-6548 in healthy volunteers.
-
IQWiG Calls For Compulsory Publication Of All Clinical Trials
12/1/2009
The Institute for Quality and Efficiency in Health Care (IQWiG) is calling for registration and publication of the results of all clinical trials to be made obligatory. The German Federal Government must push for a mandatory regulation to be implemented at EU level; in the USA this obligation has been in force since 2008.
-
Æterna Zentaris Announces Positive Results For Phase 2 Study With LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 In Endometrial Cancer
11/30/2009
Æterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, recently announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.
-
TRIN Pharma Starts Phase I Clinical Trial Of TRIN 2755 In Solid Tumors
11/12/2009
TRIN Pharma GmbH, specializing in the development of small molecule drugs for tumor treatment, announced today that BfArM, the German regulatory authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumors.
-
Homogeneous Fluorescence-Based Assay For Detecting Intracellular Calcium Mobilisation
11/12/2009
Amsbio's Screen Quest Calcium Assay kit provides a homogeneous fluorescence-based assay for detecting intracellular calcium mobilisation across a broad spectrum of biological targets.
-
New High-Shear Microplate Enables Cellular Pathology Studies With BioFlux™ Platform
11/11/2009
Fluxion Biosciences introduces a new microplate for its BioFlux live cell imaging workstations, extending their shear flow limits to simulate a variety of pathological vascular conditions.
This website uses cookies to ensure you get the best experience on our website. Learn more